Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan-Dec;16(1):2380064.
doi: 10.1080/19490976.2024.2380064. Epub 2024 Jul 29.

AIEC-dependent pathogenic Th17 cell transdifferentiation in Crohn's disease is suppressed by rfaP and ybaT deletion

Affiliations

AIEC-dependent pathogenic Th17 cell transdifferentiation in Crohn's disease is suppressed by rfaP and ybaT deletion

G Leccese et al. Gut Microbes. 2024 Jan-Dec.

Abstract

Mucosal enrichment of the Adherent-Invasive E. coli (AIEC) pathotype and the expansion of pathogenic IFNγ-producing Th17 (pTh17) cells have been linked to Crohn's Disease (CD) pathogenesis. However, the molecular pathways underlying the AIEC-dependent pTh17 cell transdifferentiation in CD patients remain elusive. To this aim, we created and functionally screened a transposon AIEC mutant library of 10.058 mutants to identify the virulence determinants directly implicated in triggering IL-23 production and pTh17 cell generation. pTh17 cell transdifferentiation was assessed in functional assays by co-culturing AIEC-infected human dendritic cells (DCs) with autologous conventional Th17 (cTh17) cells isolated from blood of Healthy Donors (HD) or CD patients. AIEC triggered IL-23 hypersecretion and transdifferentiation of cTh17 into pTh17 cells selectively through the interaction with CD-derived DCs. Moreover, the chronic release of IL-23 by AIEC-colonized DCs required a continuous IL-23 neutralization to significantly reduce the AIEC-dependent pTh17 cell differentiation. The multi-step screenings of the AIEC mutant's library revealed that deletion of ybaT or rfaP efficiently hinder the IL-23 hypersecretion and hampered the AIEC-dependent skewing of protective cTh17 into pathogenic IFNγ-producing pTh17 cells. Overall, our findings indicate that ybaT (inner membrane transport protein) and rfaP (LPS-core heptose kinase) represent novel and attractive candidate targets to prevent chronic intestinal inflammation in CD.

Keywords: AIEC; Crohn’s disease; IL-23; pathogenic Th17 cells.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

None
Graphical abstract
Figure 1.
Figure 1.
AIEC intracellular persistence within dendritic cells promotes dysregulated IL-23 hypersecretion selectively in CD patients.
Figure 2.
Figure 2.
AIEC strongly promotes the transdifferentiation of conventional Th17 cells into pathogenic IFNγ-producing pTh17 cells selectively through the interaction with CD-derived DCs.
Figure 3.
Figure 3.
Immunological and functional screening of the AIEC-LF82 mutant library on HD-and CD-derived DCs.
Figure 4.
Figure 4.
Conservation of selected AIEC-gene targets among different E. coli pathotypes and phenotypic characterization of the LF82 mutant strains.
Figure 5.
Figure 5.
Deletion of the AIEC-determinantsybaT or rfaP drastically impaired the transdifferentiation of cTh17 cells into pTh17 cells.

References

    1. Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383(27):2652–22. doi:10.1056/NEJMra2002697. - DOI - PubMed
    1. Na SY, Moon W.. Perspectives on Current and novel treatments for inflammatory bowel disease. Gut Liver. 2019;13(6):604–616. doi:10.5009/gnl19019. - DOI - PMC - PubMed
    1. Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol. 2018;11(6):1558–1570. doi:10.1038/s41385-018-0050-3. - DOI - PMC - PubMed
    1. Borody TJ, Dolai S, Gunaratne AW, Clancy RL. Targeting the microbiome in Crohn’s disease. Expert Rev Clin Immunol. 2022;18(9):873–877. doi:10.1080/1744666X.2022.2093186. - DOI - PubMed
    1. Gowen R, Gamal A, Di Martino L, McCormick TS, Ghannoum MA. Modulating the microbiome for Crohn’s disease treatment. Gastroenterology. 2023;164(5):828–840. doi:10.1053/j.gastro.2023.01.017. - DOI - PMC - PubMed

Publication types

MeSH terms